| 7.63 -0.04 (-0.52%) | 05-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.33 | 1-year : | 10.89 |
| Resists | First : | 7.98 | Second : | 9.33 |
| Pivot price | 6.71  |
|||
| Supports | First : | 5.98 |
Second : | 4.73 |
| MAs | MA(5) : | 7.09 |
MA(20) : | 6.27 |
| MA(100) : | 5.64 |
MA(250) : | 5.55 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 90.8 |
D(3) : | 79.9 |
| RSI | RSI(14): 71.1  |
|||
| 52-week | High : | 7.98 | Low : | 4.33 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CADL ] has closed below upper band by 16.4%. Bollinger Bands are 101.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 13 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 7.93 - 7.97 | 7.97 - 8 |
| Low: | 7.41 - 7.46 | 7.46 - 7.49 |
| Close: | 7.56 - 7.63 | 7.63 - 7.68 |
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
Mon, 04 May 2026
Candel Therapeutics to review Phase 3 prostate cancer data in May 15 call - Proactive financial news
Mon, 04 May 2026
Candel lines up May 15 call after prostate cancer trial data at AUA - Stock Titan
Fri, 01 May 2026
Two new Candel hires get options to buy 29,400 shares at $6.18 - Stock Titan
Wed, 29 Apr 2026
[ARS] Candel Therapeutics, Inc. SEC Filing - Stock Titan
Wed, 29 Apr 2026
Candel Therapeutics (NASDAQ: CADL) details 2026 virtual vote on directors and KPMG - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 73 (M) |
| Shares Float | 63 (M) |
| Held by Insiders | 15.7 (%) |
| Held by Institutions | 33 (%) |
| Shares Short | 15,070 (K) |
| Shares Short P.Month | 14,180 (K) |
| EPS | -0.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.94 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -26 % |
| Return on Equity (ttm) | -64.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -38 (M) |
| Levered Free Cash Flow | -46 (M) |
| PE Ratio | -10.6 |
| PEG Ratio | 0 |
| Price to Book value | 8.03 |
| Price to Sales | 0 |
| Price to Cash Flow | -14.6 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|